Can a blood marker called lumican reveal hidden fragility in postmenopausal osteoporosis
Official title: Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
Run by Kanuni Sultan Suleyman Training and Research Hospital · NCT07677072 · Data updated 2026-11-12
This study tests whether serum lumican levels can help identify hidden fragility risk in postmenopausal women beyond what bone density shows.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 45 Years and up |
| Sex | Women only |
| Enrollment | 98 (estimated) |
| Sponsor | Kanuni Sultan Suleyman Training and Research Hospital Academic / other |
| Drugs / interventions | denosumab |
| Locations | 1 site (Küçükçekmece, Istanbul) |
| Status | Recruiting |
| Started | May 15, 2026 |
| Main results expected | December 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | June 30, 2026 |
| Trial ID | NCT07677072 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are postmenopausal women 45 and older undergoing routine osteoporosis workup at the hospital who consent to blood testing.
✕Probably not a fit
Findings may not apply to premenopausal women or those not undergoing standard osteoporosis assessments, and some patients may not show a relationship between lumican and fracture risk.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective observational study enrolling about 100 postmenopausal women undergoing routine osteoporosis evaluation. Researchers will measure serum lumican levels and compare them with bone mineral density, handgrip strength, FRAX fracture risk scores, and history of falls or fragility fractures. No treatment will be given; data will come from standard clinical assessments plus a blood test for lumican. The goal is to see if lumican can uncover fracture risk not captured by BMD alone. The study is conducted at a single center in Istanbul, Turkey.
Why it matters
Potential benefit: If successful, lumican testing could help identify women at higher fracture risk who might benefit from preventive measures.
How similar studies have gone: Previous research has explored biomarkers for bone health, but this study investigates lumican specifically as an additional indicator beyond BMD.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Inclusion Criteria: * Female sex * Age 45 years or older * Postmenopausal status * Attendance at the Physical Medicine and Rehabilitation outpatient clinic * Undergoing routine bone mineral density (DEXA) assessment and osteoporosis laboratory evaluation * Ability and willingness to provide written informed consent Exclusion Criteria: Exclusion Criteria: * Premenopausal women * Secondary causes of osteoporosis (e.g., malignancy, advanced renal failure, severe liver disease, significant endocrine disorders) * Active infection or acute inflammatory disease * Major surgery within the previous 6 months * Neurological or muscular disorders that may significantly affect muscle function * Inability to comply with study procedures and assessments * Current treatment with medications that significantly affect bone metabolism, including bisphosphonates, denosumab, teriparatide, or other anti-osteoporotic agents * Refusal or inability to provide written informed consent
Where it's running
-
Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey
Küçükçekmece, Istanbul, Turkey (Türkiye) Recruiting
Study contacts
- Principal investigator: Dilek Ün oguzhanasiltürk, MD — Kanuni Sultan and Süleyman Training Resarch Hospital
- Study coordinator: Dilek Ün Oğuzhanasiltürk, MD
- Email: dilekunoguzhan@gmail.com
- Phone: +90 5056367184
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ibandronate vs. Zoledronic Acid After Denosumab: Is Either Equal for Postmenopausal Osteoporosis?
In postmenopausal osteoporosis, this study tests whether intravenous ibandronate given after stopping denosumab works as well as zoledronic acid over a year.
-
Postprandial drop and frailty in older adults having planned noncardiac surgery
This study tests whether a drop in blood pressure after meals and frailty predict low blood pressure after anesthesia starts in adults 65 and older undergoing planned noncardiac surgery.
-
Frailty Training for Emergency Nurses in Morocco
This trial tests whether a four-module training program helps Moroccan emergency nurses recognize and care for frail older adults in the ER.
-
Physical Function and Fall Risk in Older Adults in Lalín's Frailty Prevention Program
This study will look at how physical function and fall risk change in people 70 and older who participate in a routine frailty and falls prevention program, by comparing assessments before and after the 8–12 week program.
-
Home-based multicomponent exercise program for older adults with osteosarcopenia and frailty
This study tests a home-based exercise program built on the Fogg Behavior Model to see if it improves frailty, muscle strength, physical function, bone density, and quality of life in adults aged 60–85 with osteosarcopenia and frailty.
-
VIVI-OLIVE: Multicomponent Exercise and Olive Oil for Older Adults at High Risk of Falls
In adults 75 and older at high risk of falling, this study tests whether a 24-month plan of personalized exercise, Mediterranean diet guidance, and 60 mL of extra virgin olive oil daily can improve walking speed and reduce fall risk.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.